A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours

The requested reference [3910554893f7a53bc9a8872025790265d0f1ae6c] no longer exists in our database. It has been replaced by the current reference: [a09c2851190f47023e24683b951d4bb7c6766310]

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: 47a3ea1ba053c5adb10c98fd257e855bffa17110
First added on: Feb 13, 2025